Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...949596979899100101102103104...123124»
  • ||||||||||  lenvatinib / Generic mfg.
    Preclinical, Review, Journal:  Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. (Pubmed Central) -  Oct 28, 2020   
    Positive outcomes have been achieved in the combination of lenvatinib plus ICIs, bringing broader prospects for HCC. This review presents an overview on the therapeutic mechanisms and clinical efficacy of lenvatinib in HCC, and we discuss the future perspectives of lenvatinib in HCC management with focus on biomarker-guided precision medicine.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Journal:  Sequential systemic treatment in patients with hepatocellular carcinoma. (Pubmed Central) -  Oct 27, 2020   
    Sequential systemic treatment is feasible and effective in selected patients with HCC in clinical practice. Our study underlines the critical importance of well-preserved liver function for successful administration of sequential systemic therapy.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Retrospective data, Review, Journal:  Anti-Tumor Activity and Safety of Multikinase Inhibitors in Advanced and/or Metastatic Thyroid Cancer: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) -  Oct 24, 2020   
    We identified three therapies for RR-WDTC: sorafenib [disease control rate (DCR) odds ratio (OR): 0.11 (95% CI: 0.03-0.40); progression-free survival (PFS) hazard ratio (HR): 1.99 (95% CI: 1.62-2.46)], vandetanib [DCR_OR:0.26 (95% CI: 0.06-1.24); PFS_HR: 0.99 (95% CI: 0.82-1.20)] and lenvatinib [DCR_OR: 0.26 (95% CI: 0.05-1.33); PFS_HR: 0.99 (95% CI: 0.81-1.22)]; and the following therapies for MTC: vandetanib 300 mg [objective response rate (ORR)_OR: 3.31 (95% CI: 0.68-16.22); vandetanib 150 mg ORR_OR: 0.60 (95% CI: 0.16-2.33)]; and cabozantinib [ORR_OR: 85.32 (95% CI: 5.22-1395.15)]...This network meta-analysis on advanced and/or metastatic TC points towards a higher efficacy of lenvatinib in RR-WDTC. The included MKIs exhibit a varying SE profile across different organs/systems favoring a patient-tailored approach with the anticipated toxicities guiding clinicians' decisions.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Clinical, Retrospective data, Journal:  Unusual metastases from differentiated thyroid cancers: A multicenter study in Korea. (Pubmed Central) -  Oct 24, 2020   
    Unusual metastases from differentiated thyroid cancer are thought to be underestimated due to disease rarity and their metachronous nature with other distant metastases. The most of unusual metastases in differentiated thyroid cancer patients are existed with usual distant metastasis and clinical outcomes of those could not be significantly different from the prognosis of usual distant metastasis.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal, HEOR:  Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis. (Pubmed Central) -  Oct 23, 2020   
    However, in recent years, 6 new treatments have been approved by the US Food and Drug Administration (FDA): regorafenib, lenvatinib, cabozantinib, pembrolizumab, ramucirumab, and nivolumab...The pathway with the lowest CER was sorafenib, followed by pembrolizumab (USD 227,741.03/quality-adjusted life year [QALY])...All pathways exceeded a commonly accepted WTP of USD 100-150,000/QALY. Our preliminary results warrant further studies to best inform real-world practices.
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    New P2 trial, Metastases:  TACE Combined With Lenvatinib and Sintilimab for Advanced HCC (clinicaltrials.gov) -  Oct 22, 2020   
    P2,  N=30, Not yet recruiting, 
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal:  Recent progress in treatment of hepatocellular carcinoma. (Pubmed Central) -  Oct 15, 2020   
    With some potential anti-HCC drugs being reported, many promising therapeutic targets in related taxonomic signaling pathways including cell cycle, epigenetics, tyrosine kinase and so on that affect the progression of HCC have also been found. Together, the rational application of existing therapies and drugs as well as the new strategies will bring a bright future for the global cure of HCC in the coming decades.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] The role of immune checkpoint inhibitor as a single agent or combination therapy in advanced thyroid cancer () -  Oct 14, 2020 - Abstract #SITC2020SITC_1240;    
    No CR was reported, and the overall response rates (ORRs) varied from 9% (pembrolizumab monotherapy and nivolumab plus ipilimumab) to 64% (pembrolizumab plus lenvatinib) (figure 1a).1–4 In ATC, four studies have reported favorable outcomes in the context of dabrafenib and trametinib.5 The efficacy of spartalizumab, a PD1-inhibitor, was evaluated in a phase I/II trial, rendering an ORR of 19%, with 3 CRs (7%) and 5 PRs (12%) [6]...Landscape of combination checkpoint inhibition agents.Abbreviations: DTC, differentiated thyroid cancer; ATC, anaplastic thyroid cancer, MTC, medullary thyroid cancer; NIVO, nivolumab; IPI, ipilimumab; LENV, lenvatinib; ATEZO, atezolizumab; VEM, vemurafenib; COBI, cobimetinib, DAB, dabrafenib; TRAME, trametinib; PEM, pembrolizumab; DOXY, doxycycline; SBRT: Stereotactic radiation therapy...In particular, dual ICIs or combination of TKI and ICI can be developed as treatment options for ATC. Further large scale randomized prospective studies are required to establish ICIs as standard of care.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] The role of immune checkpoint inhibitor as a single agent or combination therapy in advanced thyroid cancer () -  Oct 14, 2020 - Abstract #SITC2020SITC_505;    
    No CR was reported, and the overall response rates (ORRs) varied from 9% (pembrolizumab monotherapy and nivolumab plus ipilimumab) to 64% (pembrolizumab plus lenvatinib) (figure 1a).1–4 In ATC, four studies have reported favorable outcomes in the context of dabrafenib and trametinib.5 The efficacy of spartalizumab, a PD1-inhibitor, was evaluated in a phase I/II trial, rendering an ORR of 19%, with 3 CRs (7%) and 5 PRs (12%) [6]...Landscape of combination checkpoint inhibition agents.Abbreviations: DTC, differentiated thyroid cancer; ATC, anaplastic thyroid cancer, MTC, medullary thyroid cancer; NIVO, nivolumab; IPI, ipilimumab; LENV, lenvatinib; ATEZO, atezolizumab; VEM, vemurafenib; COBI, cobimetinib, DAB, dabrafenib; TRAME, trametinib; PEM, pembrolizumab; DOXY, doxycycline; SBRT: Stereotactic radiation therapy...In particular, dual ICIs or combination of TKI and ICI can be developed as treatment options for ATC. Further large scale randomized prospective studies are required to establish ICIs as standard of care.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    [VIRTUAL] A RARE CASE OF RESPIRATORY FAILURE: ADENOID CYSTIC CARCINOMA () -  Oct 12, 2020 - Abstract #CHEST2020CHEST_1432;    
    Metastatic lesions are often recalcitrant to current treatment modalities, which highlights the need for further exploration of novel targeted therapies. Physicians should have a high degree of suspicion, especially in younger patients, to avoid the catastrophic consequences of disease progression and metastasis.
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Enrollment open, Trial initiation date, PD(L)-1 Biomarker, Metastases:  Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers (clinicaltrials.gov) -  Oct 12, 2020   
    P2,  N=44, Recruiting, 
    Physicians should have a high degree of suspicion, especially in younger patients, to avoid the catastrophic consequences of disease progression and metastasis. Not yet recruiting --> Recruiting | Initiation date: Jul 2020 --> Oct 2020
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Trial initiation date, PD(L)-1 Biomarker, Metastases:  Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Oct 12, 2020   
    P2,  N=76, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2020 --> Oct 2020
  • ||||||||||  lenvatinib / Generic mfg.
    [VIRTUAL] THE RELATIONSHIP BETWEEN OUTCOMES AND RELATIVE DOSE INTENSITY TREATED WITH LENVATINIB () -  Oct 11, 2020 - Abstract #AASLD2020AASLD_1177;    
    Advanced portal hypertension was associated with the therapeutic efficacy of lenvatinib in controlling the progression of HCC in patients with low-RDI or in patients with poor liver function. Our study revealed the importance of achieving RDI equal to or over 70% at the first 30 days to maximize the effect of lenvatinib.
  • ||||||||||  lenvatinib / Generic mfg.
    [VIRTUAL] REAL-WORLD SAFETY AND TOLERABILITY DATA FOR LENVATINIB USE IN UNRESECTABLE HEPATOCELLULAR CANCER () -  Oct 11, 2020 - Abstract #AASLD2020AASLD_1167;    
    Lenvatinib was used as first-line systemic therapy in 80% and second-line therapy in 20% (all had previously received sorafenib and were intolerant [n=7] or developed disease progression [n=3]). The safety profile of lenvatinib in patients with unresectable HCC was similar to those seen in initial clinical trials, however, hypothyroidism occurred more frequently (39%) in this real-world cohort.